ALLMedicine™ Multiple Sclerosis Center
Research & Reviews 23,399 results
Journal of Cerebral Blood Flow and Metabolism : Official ... van der Weijden CW, van der Hoorn A et. al.
Jun 28th, 2022 - Neuronal damage is the primary cause of long-term disability of multiple sclerosis (MS) patients. Assessment of axonal integrity from diffusion MRI parameters might enable better disease characterisation. 16 diffusion derived measurements from dif...
Journal of Visualized Experiments : JoVE; Cheng L, Su L et. al.
Jun 28th, 2022 - Lysophospholipids (LPLs) are bioactive lipids that include sphingosine 1-phosphate (S1P), lysophosphatidic acid, etc. S1P, a metabolic product of sphingolipids in the cell membrane, is one of the best-characterized LPLs that regulates a variety of...
PloS One; Petržalka M, Meluzínová E et. al.
Jun 28th, 2022 - The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed....
Multiple Sclerosis and Related Disorders; Bove R, Hellwig K et. al.
Jun 27th, 2022 - Most disease-modifying therapies (DMTs) approved for the treatment of multiple sclerosis (MS) are not recommended during pregnancy, and discouraged while breastfeeding. However, discontinuation of some DMTs before pregnancy can leave women vulnera...
Multiple Sclerosis and Related Disorders; Broch L, Flemmen HØ et. al.
Jun 27th, 2022 - Fatigue is one of the leading causes of reduced quality of life and inability to work in people with multiple sclerosis (pwMS). Currently, no treatment effectively ameliorates fatigue. We still know little about what causes fatigue and which facto...
Guidelines 16 results
Archives of Physical Medicine and Rehabilitation; Rider JV, Selim J
Jun 18th, 2022 - Supporting the Role of Parenting for People with Multiple Sclerosis: A Guide for Clinicians.|2022|Rider JV,Selim J,|
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.
Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|
Neurology Kapoor R, Smith KE et. al.
Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.
May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.
Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...
Drugs 389 results see all →
Clinicaltrials.gov 2,551 results
Jun 24th, 2022 - Objective Multiple inflammatory and neurodegenerative mechanisms drive progression of disability in fully established multiple sclerosis (MS); therefore, it is unlikely that a single therapeutic agent will be curative. Analogous to cardiovascular ...
Jun 24th, 2022 - This is a two cohort, multicenter, open-label, prospective study of 40 (optionally up to 60) patients with relapsing multiple sclerosis (RMS) planning to undergo a SARS-CoV-2 mRNA vaccination (initial vaccinations or booster vaccines) as part of c...
Jun 24th, 2022 - This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive o...
Jun 24th, 2022 - Objective: The overall goal of this study is to determine the safety, tolerability, and radiological efficacy of up to 12 weeks of subcutaneous injection of anakinra in people with multiple sclerosis and evidence, by magnetic resonance imaging (MR...
Jun 24th, 2022 - Studies performed under 89-N-0045 are primarily designed to examine the evolving natural history of multiple sclerosis (MS) and its mimickers, viewed through the window of neuroimaging (especially magnetic resonance imaging or MRI). The protocol h...
News 3,976 results
Jun 23rd, 2022 - DENVER – Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contribute to, ac.
Jun 23rd, 2022 - DENVER, Colorado — Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contrib...
Jun 22nd, 2022 - The novel drug vidofludimus calcium (Immunic Therapeutics) is safe and effective for patients with relapsing-remitting multiple sclerosis (RRMS), new research suggests. Vidofludimus calcium is an investigational oral second-generation selective di...
Jun 21st, 2022 - NATIONAL HARBOR, Maryland ― The latest updates on COVID-19 vaccination response among patients with multiple sclerosis (MS) who are treated with disease-modifying therapy (DMT) show that if patients do contract the virus, cases are mild, and serio...
Jun 20th, 2022 - NATIONAL HARBOR, Maryland — The first randomized trial to examine whether older adults with multiple sclerosis (MS) can safely discontinue disease-modifying therapy (DMT) after years of being relapse-free failed to deliver a definitive conclusion....